1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Ipsen’s Onivyde Hits Bullseye In Pivotal First-Line Pancreatic Cancer Trial

But Observers Waiting To Raise Sales Projections

 
• By Ayisha Sharma

The French firm’s Onivyde has succeeded as part of a combination regimen in chemotherapy-naïve pancreatic cancer patients, setting it up for a label expansion, but some experts are keen to see survival data in full before raising guidance.  

Arrow hitting the bullseye on an archery board
Onivyde Is Set For A Label Expansion For Untreated Pancreatic Cancer • Source: Shutterstock

Ipsen SA’s Onivyde (irinotecan liposome injection) has met the primary endpoint of overall survival (OS) in a Phase III trial in untreated pancreatic cancer patients, sparking filing plans, but potential sales depend on data yet to be released, some observers say.

The Phase III NAPOLI 3 trial set Onivyde plus oxaliplatin (Sanofi’s Eloxatin) and 5 FU/LV against gemcitabine (Eli...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Dynavax Aims To Disrupt GSK’s Shingrix Market With More Tolerable Shingles Vaccine

 
• By Mandy Jackson

Phase I/II head-to-head data show Dynavax’s Z-1018 had similar immunogenicity and much improved tolerability versus Shingrix, prompting a move into Part 2 of the study.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

More from R&D

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger